TLR4-C34, a TLR4 inhibitor.

TLR4-C34 is a TLR4 inhibitor that inhibits TLR4 signaling in enterocytes and macrophages in vitro. The innate immune receptor toll-like receptor 4 (TLR4) is a pattern recognition receptor expressed in both hematopoietic and non-hematopoietic cells. C34 is a 2-acetamidopyranoside that inhibits TLR4 in IEC-6 enterocytes and RAW264.7 macrophages in vitro at a dosage of 10μM. Pretreatment with 1mg/kg C34 30 minutes before LPS (3mg/kg) injection significantly reduced luciferase activity in mice. In a mouse model of experimental necrotizing enterocolitis (NEC), oral gavage of C34 (1mg/kg/day) for 4 days attenuated the severity of NEC as demonstrate by marked preservation of the intestinal mucosa, downregulation of pro-inflammatory iNOS expression, and reduced NEC severity score. C34 at 10μM inhibited TLR4 signaling ex vivo in human tissues isolated from infants with NEC.

Product information

CAS Number: 40592-88-9

Molecular Weight: 389.40

Formula: C17H27NO9

Synonym:

TLR4-C34

TLR4 C 34

C34

C 34

C-34

TLR4-IN-C34

Toll-Like Receptor 4-C34

TLR4-C-34

TLR4-C 34

Chemical Name: (2R,3S,4R,5R,6S)-5-acetamido-2-(acetoxymethyl)-6-isopropoxytetrahydro-2H-pyran-3,4-diyl diacetate

Smiles: CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O

InChiKey: KMIQMFHPUJUDMC-HHARLNAUSA-N

InChi: InChI=1S/C17H27NO9/c1-8(2)24-17-14(18-9(3)19)16(26-12(6)22)15(25-11(5)21)13(27-17)7-23-10(4)20/h8,13-17H,7H2,1-6H3,(H,18,19)/t13-,14-,15-,16-,17+/m1/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

TLR4-IN-C34 (C34, 1 mg/kg, orally daily) could attenuate NEC severity and demonstrates a marked preservation of the intestinal mucosa.

References:

1. Neal MD, et al. Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. PLoS One. 2013 Jun 12;8(6):e65779.
2. Wipf P, et al. Synthesis of anti-inflammatory α-and β-linked acetamidopyranosides as inhibitors of toll-like receptor 4 (TLR4). Tetrahedron Lett. 2015 Jun 3;56(23):3097-3100.

Products are for research use only. Not for human use.